Our purpose is attracting strategic partnerships and investment from companies at the forefront of pharmaceutical and medical device innovation. We envision this device revolutionizing treatment across a broad spectrum of diseases, including gastroenterological, hematological, infectious, neurological, psychiatric, endocrinological, nutritional, genitourinary, and respiratory conditions. We are targeting pharmaceutical companies, medical device manufacturers, and technology firms engaged in advanced microchip development, interested in collaborations for development and commercialization.

Our drug delivery device is currently at Technology Readiness Level (TRL) 4, indicating that its core components have been validated in a lab environment. Our immediate next steps involve advancing to TRL 5 and beyond through rigorous preclinical testing to validate the device’s efficacy and safety in relevant biological models.

The SINDREL technology, with its modular design and graphene-based platform, inherently supports scalability. Its adaptable nature allows for diverse drug payloads and therapeutic applications, addressing varied market demands. The efficient production of graphene nanocomposites and miniaturized electronics, coupled with a flexible software interface for personalized control, enables high-scale manufacturing while maintaining high quality standards. For investors, this design facilitates efficient resource utilization, driving increased revenue per unit as demand for personalized, on-demand drug delivery grows across multiple disease areas, proving its capacity to do more with less in a competitive market.

The SINDREL technology is engineered for high replicability, enabling consistent delivery of the personalized drug delivery system across diverse markets. The standardized fabrication processes for the graphene-based nanocomposites and the integration of off-the-shelf microprocessor components ensure uniform product quality. Furthermore, the digital nature of the control system, managed through a user-friendly application, allows for identical functionality and user experience regardless of geographic location. This inherent design for consistent manufacturing and reliable performance ensures that the exact same high-standard service and product can be provided to an theoretically infinite customer base.

The SINFDREL technology and its proposed business model are designed for long-term sustainability, extending value beyond immediate economic returns. Our sustainable value proposition lies in providing highly personalized, efficient, and less invasive drug delivery, which minimizes waste, improves patient outcomes, and potentially reduces healthcare system burden. This value is created through the precise, on-demand drug release mechanism, leveraging graphene’s properties, and delivered via a user-friendly, adaptable device. Economically, we capture value through sales and licensing, while maintaining and regenerating natural, social, and economic capital by fostering health, reducing medication waste, and contributing to the advanced materials and biomedical sectors. Our focus is on adding value to patients, healthcare providers, and the broader society by offering a truly sustainable, high-quality therapeutic solution.